The Wistar Institute

University of Pennsylvania

Genetics Institute, Inc.

Other

Johns Hopkins University

Wyeth

Giorgio Trinchieri

Gordon G Wong

Steven C Clark

Rodney M Hewick

Bice Perussia

Michiko Kobayashi

Stanley F Wolf

Phillip Scott

James M Wilson

Yiping Yang

Christopher L Karp

Diane E Griffin

Maria Wysocka

Nicholas M Valiante

This application relates to antibodies reactive with a novel homogenous human cytokine, Natural Killer Stimulator Factor (NKSF), having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing such antibodies.

Natural killer stimulatory factor

Antibodies to natural killer stimulatory factor

A method of reducing immune response to a viral vector containing a selected transgene is provided. The method involves co-administration of the viral vector and a selected immune modulator capable of inhibiting the formation of neutralizing antibodies and/or CTL elimination of the vectors upon repeated administration.

Method of reducing an immune response to a recombinant virus

Antibodies reactive with a novel homogeneous human cytokine, Natural Killer Stimulatory Factor, (NKSF), NKSF having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing such antibodies.

Improved vaccine compositions and methods of making same are provided, which vaccines are characterized by an antigen from a pathogen and an effective adjuvanting amount of Interleukin-12. These IL-12 adjuvanted vaccines are capable of increasing the vaccinated host's cell mediated immune response to provide an increased and protective immune response to the pathogen. Also disclosed are methods for vaccinating hosts by administering a vaccine containing an antigen from a pathogenic microorganism and co-administering an adjuvanting amount of IL-12. Vaccines or therapeutic compositions directed against a cancer may also be adjuvanted with IL-12 according to this invention.

Compositions and methods for use of IL-12 as an adjuvant

The invention includes compositions and methods for selective suppression of IL-12 production in a cell. Methods of treating a human having a disease associated with dysregulated IL-12 production are also provided.

Methods and compositions for the inhibition of interleukin-12 production

A method of reducing an immune response to a recombinant adenovirus which involves co-administration of the recombinant adenovirus and a selected immune modulator. The immune modulator functions by inhibiting the formation of neutralizing antibodies and/or reducing CTL killing of the virally infected cells. The method additionally encompasses the step of re-administering the recombinant adenovirus.

Method of reducing an immune response to a recombinant adenovirus

A novel homogeneous human cytokine, Natural Killer Stimulatory Factor, having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing it.

The present invention provides a novel monoclonal antibody, mAb C1.7, and its antigenic receptor, p38, which is an NK cell and CD8.sup.+ T cell activating structure. Methods of using these compositions to identify and monitor the course of a disease, as well as for therapeutic purposes, are disclosed.

Human cytotoxic lymphocyte signal transduction surface protein (P38) and

Methods of inducing gamma interferon production and stimulating lymphocyte populations using Natural Killer Stimulatory Factor (NKSF) are disclosed.

Methods of inducing gamma interferon and stimulating blood cell

Natural killer cell stimulatory factor

Improved vaccine compositions and methods of making the compositions are provided, which vaccines are characterized by an antigen from a pathogen and an effective adjuvanting amount of Interleukin-12 (IL-12). These IL-12 adjuvanted vaccines are capable of increasing the vaccinated host's cell mediated immune response to provide an increased and protective immune response to the pathogen. Also disclosed are methods for vaccinating hosts by administering a vaccine containing an antigen from a pathogenic microorganism and co-administering an adjuvanting amount of IL-12. Vaccines or therapeutic compositions directed against a cancer may also be adjuvanted with IL-12 according to this invention.

Growing community of inventors

Wynnewood, PA, United States of America

Giorgio Trinchieri